Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1128/JVI.01105-15 http://scihub22266oqcxt.onion/10.1128/JVI.01105-15 C4524072!4524072!26085169     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Virol 2015 ; 89 (17): 9124-7 Nephropedia Template TP {{tp|p=26085169|t=2015. Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy |pdf=|usr=}}{{26085169}} gab.com Text Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy JO: J Virol http://www.kidney.de/pget.php?&tw=1&pmid=26085169 #FOAvip Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8+ T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy. Twit Text FOAVip Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy ????J Virol http://www.kidney.de/pget.php?&tw=1&pmid=26085169 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26085169 #FOAvip English Wikipedia <ref>{{Cite pmid|26085169}}</ref> Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy #MMPMID26085169 Oreshkova N; Spel L; Vloet RPM; Wichgers Schreur PJ; Moormann RJM; Boes M; Kortekaas J J Virol 2015[Sep]; 89 (17): 9124-7 PMID26085169show ga Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8+ T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy. äPreliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy(epmc).pdf DeepDyve Pubget Overpricing